Table 5.
Immunohistochemical results in ALCL and CHL
| Lymphoma group | CD30 | CD15 | p63 | ALK | PAX-5 | CD45 | EMA | Clusterin | CD20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| ALCL (n = 154) (%) | Total | 154 (100) | 3 * (1.9) | 68 (44.2) | 49 (38.8) | 5 (3.2) | 91 (59) | 79 (51) | 58 (38) | 0 |
| T-cell (n = 92) | 92 (59.7) | 1 (1.1) | 46 (50) | 8 (16.3) | 5 (5.4) | 57 (62) | 35 (38) | 34 (37) | 0 | |
| N cell (n = 62) | 62 (40.3) | 2 (3.2) | 22 (35.5) | 41 (83.7) | 0 | 34 (54.8) | 44 (71) | 24 (39) | 0 | |
| HL (n = 58) (%) | CHL (n = 51) | 51 (100) | 45 (88.2) | 0 | 0 | 34 (66.7) | 0 | 4 (7.8) | 11 (22) | 8 (16) |
| NLPHL (n = 7) | 0 | 0 | 2 (28.6) | 0 | 7 (100) | 7 (100) | 0 | ND | 7 (100) |
Abbreviation: NLPHL, nodular lymphocyte predominance HL.
*
All 3 cases were PAX-5 and CD20 negative and LCA positive.